Therapy (HBV)

Ribozyme Targets Hepatitis B RNA Transcripts

Published in Gene Therapy Weekly, February 1st, 2001

Ribozyme Pharmaceuticals, Inc. (RPI) (RZYM), Boulder, Colorado, announced the selection of its product candidate, HepBzyme, targeting the hepatitis B virus (HBV).

This ribozyme targets several HBV RNA transcripts as well as HBV pregenomic RNA. HepBzyme represents a completely new approach to treating HBV, differing significantly from existing therapies. HepBzyme is RPI's fourth product candidate, the first three being Angiozyme, Heptazyme, and Herzyme. RPI intends to file an IND (Investigational New Drug) and complete a Phase I clinical trial for HepBzyme in 2001.

HepBzyme was selected based in part on antiviral activity screening in cell culture...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-02-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry